Related Experiment Video
Updated: May 13, 2025
06:48
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
Published on: May 31, 2020
5.8K
Ameloblastoma Diagnosis From Serum Metabolic Profiling
Peiyin Sun1, Shuai Wang2, Yali Wang1
1General Dentistry, Shanghai Children's Medical Center, School of Medicine, Jiaotong University, Shanghai, China.
Oral Diseases
|April 15, 2025
Summary
This study identified 32 dysregulated metabolites in ameloblastoma (ABM) serum, developing a 10-metabolite panel for 100% accurate ABM diagnosis. The BRAF V600E mutation is linked to altered metabolism in ABM.
Area of Science:
- Biochemistry
- Oncology
- Metabolomics
Background:
- Ameloblastoma (ABM) is an aggressive odontogenic neoplasm with unknown molecular pathogenesis.
- Investigating ABM's metabolic profile may reveal diagnostic and prognostic biomarkers.
Purpose of the Study:
- To identify distinct metabolic characteristics of ABM.
- To establish a reliable diagnostic model for ABM using serum metabolites.
- To explore the relationship between BRAF V600E mutation and metabolic reprogramming in ABM.
Main Methods:
- Serum metabolomic analysis using gas chromatography-mass spectrometry (GC-MS) on 21 ABM patients and 20 healthy controls.
- Biomarker screening and validation via LASSO regression and receiver operating characteristic analysis.
- BRAF V600E immunohistochemistry on ABM tissue samples.
Main Results:
- Identified 73 metabolites, with 32 significantly dysregulated (30 downregulated) in ABM.
- Developed a 10-metabolite diagnostic panel with 100% sensitivity, 100% specificity, and an AUC of 1.00.
- Found an association between BRAF-V600E mutation and increased serum glutamine levels in ABM.
Conclusions:
- Distinct metabolic alterations characterize ABM.
- A novel diagnostic model for ABM has been established.
- The BRAF V600E mutation may play a role in ABM's metabolic reprogramming.
